Spinosad

Summary

Spinosad (CHEMBL4297065) is an approved small molecule; indicated across 1 condition including lice infestation.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 24
• Chemistry: 1477.9 Da · C83H132N2O20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297065
Name	Spinosad
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	145946918
Molecular formula	C83H132N2O20
Molecular weight	1477.9
InChIKey	JFLRKDZMHNBDQS-UCQUSYKYSA-N

SMILES: CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C

IUPAC name: (1S,2S,5R,7S,9S,10S,14R,15S,19S)-15-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-4,14-dimethyl-7-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione;(2R,5S,7R,9R,10S,14R,15S,19S)-15-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-14-methyl-7-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione

Also known as: Blackhawk, Comfortis, Conserve, DE-105, Entrust, Extinosad, Justice, LY-232105, Natroba, Natrova, Naturalyte, PP-105

Patent coverage: 630 distinct patent families (811 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lice infestation	4	MONDO:0003472	MONDO:0003472

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
Not specified	14
PHASE4	2
PHASE3	2
PHASE2	2
EARLY_PHASE1	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01660321	PHASE4	COMPLETED	Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
NCT05310734	PHASE4	UNKNOWN	PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
NCT00545168	PHASE3	COMPLETED	Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
NCT00545753	PHASE3	COMPLETED	Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
NCT06616142	PHASE1/PHASE2	RECRUITING	Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
NCT06940427	PHASE2	RECRUITING	Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
NCT04072315	PHASE2	COMPLETED	Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
NCT02919319	PHASE1	COMPLETED	A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects
NCT05183048	EARLY_PHASE1	RECRUITING	Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
NCT02610920	EARLY_PHASE1	WITHDRAWN	Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection
NCT04646460	Not specified	NOT_YET_RECRUITING	Context Interventions: Social Modeling and Initial Treatment Experience
NCT06074198	Not specified	ACTIVE_NOT_RECRUITING	Sickle Cell Children’s Exercise Study (SuCCESs)
NCT06202898	Not specified	RECRUITING	Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)
NCT06607146	Not specified	RECRUITING	Assessing the Effect of Computer-based Auditory Training on Adult Cochlear Implant Speech and Quality-of-life Outcomes
NCT06869512	Not specified	RECRUITING	Cooperative Extension and Cancer Survivorship
NCT06896071	Not specified	RECRUITING	Evaluating a Digital Single-session Intervention for Adolescent Mental Health in New Zealand
NCT07112066	Not specified	RECRUITING	Multimodality Cardiac Imaging for Disease Progression in ATTR-CM
NCT01353326	Not specified	COMPLETED	Bone Mineral Density (BMD) in Cemented Versus Cementless Hip Resurfacing
NCT02563834	Not specified	COMPLETED	A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism
NCT02566291	Not specified	COMPLETED	Observational Study With Investigation of Two Second Generation Laryngeal Masks
NCT03177525	Not specified	COMPLETED	Parent Training to Enhance Social Success for Children With Autism Spectrum Disorder
NCT04806321	Not specified	COMPLETED	Project SOLVE: Trial of a Brief Digital Problem-solving Intervention
NCT05350514	Not specified	COMPLETED	Preclinical Imaging Biomarkers of Alzheimer’s Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study
NCT06405165	Not specified	COMPLETED	Jigsaw Learning Model and Urinary Catheter Care

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).